Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology

Yongchel Ahn¹, Heui June Ahn¹, Dok Hyun Yoon², Jung Yong Hong², Changhoon Yoo², Shin Kim², Jooryung Huh³, Cheolwon Suh²
¹Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, ²Department of Oncology, ³Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background
Age and performance status are important prognostic factors in primary central nervous system (CNS) lymphoma. Although several prognostic models have been proposed, there is no consensus on the optimal model for patients with diffuse large B-cell histology.

Methods
Seventy-seven patients with primary CNS diffuse large B-cell lymphoma were retrospectively analyzed to determine factors affecting survival. Three Western models were applied to our eligible patients; we devised a novel model based on our findings.

Results
The median patient age was 59 years (range, 29–77); the median event-free and overall survival (OS) durations were 35.9 and 12.6 months, respectively. Nottingham/Barcelona and Memorial Sloan Kettering Cancer Center models were applicable to our cohorts. Multivariate analysis showed that advanced age, multifocal lesions, and high cerebrospinal fluid (CSF) protein concentrations were correlated significantly. A novel model for predicting prognosis was then developed based on these variables. Each variable was assigned 1 point; patients with a total score of 0, 1, 2, and 3 were categorized into the low-, moderate-, high-, and very high-risk groups, respectively. Sixty-one patients were eligible considering our model; the median OS was 58.2, 34.8, 9.0, and 1.8 months in the low-, moderate-, high-, and very high-risk groups, respectively (P< 0.01).

Conclusion
Advanced age, multifocal lesions, and high CSF protein concentration were adversely related with prognosis. Our model can be helpful in pre-treatment risk stratification for patients with primary CNS lymphoma with diffuse large B-cell histology.

Key Words  Central nervous system, Lymphoma, Prognosis, Survival

INTRODUCTION

Primary central nervous system lymphoma (PCNSL) is among the most aggressive variants of extranodal non-Hodgkin lymphoma that involves the brain, cranial nerves, meninges, eyes, or spinal cord. It is known to be sensitive to both radiotherapy and chemotherapy. However, this sensitivity does not guarantee high yields of disease control or cure [1]. Although new therapeutic strategies have improved treatment outcomes, they are rarely curative. PCNSL tends to recur and carry a dismal prognosis in most patients.

Several prognostic factors influence patient survival [2-7]. Of these, the most consistent variables are patient age and performance status. To date, 3 Western prognostic models have been proposed. The first model was proposed by the International Extranodal Lymphoma Study Group (IELSG) in 2003 and is composed of 5 prognostic variables: age more than 60 years, Eastern Cooperative Oncology Group (ECOG) performance status more than 1, elevated level of serum lactate dehydrogenase (LDH), high cerebrospinal (CSF) protein concentration, and involvement of the deep regions
of the brain such as the periventricular regions, basal ganglia, brainstem, and/or cerebellum [8]. However, this model has some limitations such as the relatively small number of patients (N=105) and short follow-up period (median, 24 mo). Another European organization devised a 4-point scoring system using age, ECOG performance status, and multifocal disease [9]. However, the Nottingham/Barcelona prediction scoring system also has its own drawbacks originating from the small number of patients (N=77), discrimination issues between stratified risk groups (score 1 group vs. score 2 group), and use of old-fashioned chemotherapeutic regimens. Finally, the Memorial Sloan-Kettering Cancer Center (MSKCC) proposed a simple but statistically powerful model using only age and performance status in 2006 [6]. However, this model may have an inherent selection bias because retrospective data were collected from a single large institution.

Additionally, some studies reviewed the natural course and treatment outcomes of Asian patients [10-13]. However, their findings were also derived from retrospective, heterogeneous cohorts. We reviewed the clinical characteristics and survival outcomes of patients with pathologically diagnosed PCNSL with pure diffuse large B-cell histology. Moreover, prior models were validated, and we developed a new model for pretreatment risk stratification.

**MATERIALS AND METHODS**

**Patients**
Seventy-seven patients with PCNSL diagnosed at least 18 months before enrollment between October 1998 and March 2012 in Asan Medical Center were enrolled in this study. Patients who met the following inclusion criteria were recruited to maximize homogeneity of the study cohort: a) histologically proven diffuse large B-cell lymphoma of PCNSL; b) immune competent at diagnosis without any evidence of human immunodeficiency virus infection or other congenital immunodeficiency; c) disease localized only in the brain, cranial nerves, meninges, eyes (excluding the orbit or ocular adnexa), or spinal cord; and d) no prior history of malignancy.

Patient information including age, gender, ECOG performance status, and treatment modalities was retrieved from medical records. All patients were pathologically confirmed to have primary CNS diffuse large B-cell lymphoma by experienced pathologists in our institution based on the World Health Organization criteria [14]. Radiologic reviews were performed using Picture Archiving and Communication System. Multifocal disease was defined as more than one lesion found in radiologic evaluation, and deep regions of the brain were defined as the periventricular regions, basal ganglia, brainstem, and/or cerebellum.

**Staging and response evaluation**
Staging evaluations involved a physical examination, including slit-lamp assessment; contrast-enhanced magnetic resonance imaging (MRI) of the brain; computed tomography (CT) of the thorax, abdomen, and pelvis; lumbar puncture and CSF cytology and protein measurements (normal value: 15–45 mg/dL) if not contraindicated; bilateral bone marrow aspiration and biopsy; HIV serology test; complete blood cell count with differential count; liver and kidney function tests; serum LDH (normal level: 140–250 IU/L); and β2-microglobulin (β2-MG, normal level: 1.0–2.4 mg/L) level.

Treatment responses were assessed according to the

| Table 1. Patient characteristics. |
|----------------------------------|
| **Variables**                  | **N** | **%** |
| Age (yr)                        |       |      |
| Median (range)                  | 59    | 29-77|
| ≥65                             | 26    | 33.8 |
| Gender                          |       |      |
| Male                            | 49    | 63.6 |
| Performance status              |       |      |
| ECOG ≥2 (or KPS < 70)           | 20    | 26.0 |
| Multifocal lesions              | 19    | 24.7 |
| Ocular involvement              | 1     | 1.3  |
| Involvement of deep region in the brain | 40    | 51.9 |
| Positive CSF cytology           | 4/60  | 6.7  |
| High CSF protein level (>45 mg/dL) | 30    | 49.2 |
| Elevated serum LDH (>250 IU/L) | 41/74 | 55.4 |
| Elevated serum β2-microglobulin (>2.4 mg/L) | 7/50 | 12.1 |
| First-line treatment            |       |      |
| Chemotherapy alone              | 35    | 45.4 |
| Chemotherapy followed by WBRT   | 10    | 13.0 |
| Chemotherapy followed by ASCT   | 26    | 33.8 |
| RT alone                        | 2     | 2.6  |
| Best supportive care            | 4     | 5.2  |
| Overall response to first-line treatment |       |      |
| CR                              | 44/73 | 60.3 |
| PR                              | 13/73 | 17.8 |
| SD                              | 5/73  | 6.8  |
| PD                              | 3/73  | 4.1  |
| NE                              | 8/73  | 11.0 |
| IELSG prognostic score 0–1      | 21/61 | 34.4 |
| 2–3                             | 28/61 | 45.9 |
| 4–5                             | 12/61 | 19.7 |
| Nottingham/Barcelona prediction score |       |      |
| 0                              | 26    | 33.8 |
| 1                              | 32    | 41.6 |
| 2                              | 14    | 18.2 |
| 3                              | 5     | 6.5  |
| MSKCC prognostic model Class 1  | 19    | 24.7 |
| Class 2                         | 42    | 54.5 |
| Class 3                         | 16    | 20.8 |

Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CSF, cerebrospinal fluid; ECOG, Eastern Cooperative Oncology Group; IELSG, International Extranodal Lymphoma Study Group; KPS, Karnofsky Performance Status; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center; NE, not evaluable; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; WBRT, whole brain radiotherapy.
International Group for P3CNSL criteria [15]. Routine follow-up imaging (MRI or CT) and ophthalmologic examinations were performed every 3 months for the first 2 years, every 6 months for the next 3 years, and every year thereafter or whenever clinically indicated.

IELSG, Nottingham/Barcelona, and MSKCC prognostic models

The IELSG prognostic scoring system uses 5 unfavorable variables, namely, age more than 60 years, performance status more than 1, elevated LDH level, high CSF protein concentration, and involvement of deep regions of brain. And each value is assigned a score of 1 that are then added to yield a final score (0 to 1 score group; 2 to 3 score group; 4 to 5 score group) [8]. The Nottingham/Barcelona model incorporates 3 variables, namely, age 60 years or older, ECOG performance status more than 1, and multifocal disease. Giving 1 point for each adverse variable, the risk groups are divided into 4 types (0, 1, 2, and 3) [9]. Meanwhile, the MSKCC prognostic score is a simplified index that uses only age and Karnofsky Performance Status Scale (KPS scale) and has 3 prognostic classes: class 1 (age < 50 yr), class 2 (age ≥50 yr or KPS ≥70%), and class 3 (age ≥50 yr and KPS < 70%) [6].

Statistical analysis

Overall survival (OS) was defined as the time from the date of diagnosis to death from any cause or to the date of last follow-up. Event-free survival (EFS) was calculated from the date of diagnosis to that of relapse, disease progression, death from any cause, or last follow-up. OS and EFS were estimated using the Kaplan-Meier method and were compared using the log-rank test. Multivariate analyses were carried out using the Cox proportional hazards model. A two-sided P-value of less than 0.05 was considered statistically significant. All analyses were performed using SPSS statistical software package, version 19.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Patient characteristics and treatment

The median age was 59 years (range, 29–77 yr), and 63.6% of the cohort were men. Fifty-seven patients (74.0%) had an ECOG performance score less than 2. All the patients had parenchymal brain disease, and 6 patients (7.8%) had additional extracranial involvements, namely 4 meningeal involvements (positive CSF cytology), 1 ocular involvement, and a spinal cord lesion. Nineteen patients (24.7%) had multiple lesions, and 40 patients (51.9%) had tumor(s) in the deep regions of the brain. Sixty-one patients underwent lumbar puncture, and 30 of them (49.2%) had high CSF protein concentrations.

Seventy-one patients (92.2%) received chemotherapy as first-line treatment, with 60 (84.5%) receiving high-dose methotrexate (MTX)-based regimens. Two patients received whole brain radiotherapy (WBRT) alone, and the other 4 best supportive care. Of the 73 evaluable patients, 57 (78.1%) achieved complete response (CR) or partial response (PR) after completion of initial treatment. Meanwhile, 26 patients (45.6%) further underwent autologous stem cell transplantation (ASCT). The detailed clinical features of the patients are listed in Table 1.

Table 2. Responses to first-line treatment.

| Responses | Non-ASCT (N=47) | CTx-ASCT (N=26) |
|-----------|-----------------|-----------------|
|           | CTx only (N=35) | CTx-WBRT (N=10) | WBRT only (N=2) | Non-ASCT |
| CR        | 15 (42.9%)      | 4 (40.0%)       | 2 (100%)        | 21 (44.7%) |
| PR        | 5 (14.3%)       | 5 (50.0%)       | 0               | 10 (21.3%) |
| SD        | 4 (11.4%)       | 1 (10.0%)       | 0               | 5 (10.6%)  |
| PD        | 3 (8.6%)        | 0               | 0               | 3 (6.4%)   |
| NE        | 8 (22.9%)       | 0               | 0               | 8 (17.0%)  |
| ORR       | 61.2%           | 90%             | 100%            | 66.0%      |

Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CTx, chemotherapy; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; WBRT, whole brain radiotherapy.
deep region of the brain, and high serum LDH level were not statistically significant predictive factors of survival. In addition, when comparing the high-dose MTX chemotherapy group (N=60) with the other chemotherapy group (N=11), no statistically significant differences in median OS were noted (34.8 mo, 95% CI, 12.3–57.3 mo vs. 44.5 mo, 95% CI, 0.0–132.3 mo) (P=0.58). In multivariate analysis, age 65 years or older, multifocal lesions, and high CSF protein concentrations were associated with poor prognosis. The median EFS was 12.6 months (95% CI, 6.2–19.0 mo). EFS

| Table 3. Results of univariate analysis. |
|----------------------------------------|
| Overall survival                       |
| Event-free survival                    |
| Median (mo)                            |
| P                                      |
| Median (mo)                            |
| P                                      |
| Age                                    |
| ≥65 (N=26)                             |
| 17.4 (5.4–29.4)                        |
| <0.01                                  |
| 8.8 (0.0–18.2)                         |
| 0.67                                   |
| <65 (N=51)                             |
| 48.1 (27.2–69.0)                      |
| 0.84                                   |
| 14.4 (3.9–24.9)                       |
| 0.88                                   |
| Gender                                 |
| Male (N=49)                            |
| 35.9 (15.9–55.9)                      |
| 0.15                                   |
| 9.7 (2.5–16.9)                        |
| 0.59                                   |
| Female (N=28)                          |
| 34.8 (0.0–70.0)                       |
| 2 or more (N=20)                      |
| 20.6 (0.0–50.7)                       |
| <0.01                                  |
| 9.6 (4.9–14.3)                        |
| 0.01                                   |
| 0 or 1 (N=57)                         |
| 43.4 (27.6–59.2)                      |
| <0.01                                  |
| 14.4 (7.6–21.2)                       |
| Multifocal lesions                     |
| Yes (N=19)                             |
| 11.2 (7.1–15.3)                       |
| 0.97                                   |
| 6.0 (1.6–10.4)                        |
| 0.58                                   |
| No (N=58)                              |
| 44.5 (30.9–58.1)                      |
| 0.97                                   |
| 18.9 (0.0–42.2)                       |
| Deep region                            |
| Yes (N=40)                             |
| 34.8 (21.6–48.0)                      |
| 0.01                                   |
| 9.7 (2.9–16.5)                        |
| 0.27                                   |
| No (N=37)                              |
| 41.9 (21.3–62.5)                      |
| 0.01                                   |
| 15.0 (0.0–44.7)                       |
| High CSF protein concentration         |
| Yes (N=30)                             |
| 18.1 (0.95–35.3)                      |
| 0.01                                   |
| 6.2 (0.0–27.6)                        |
| 0.27                                   |
| No (N=31)                              |
| 48.1 (27.8–68.4)                      |
| 0.01                                   |
| 15.0 (0.0–37.1)                       |
| Serum LDH                              |
| Elevated (N=41)                        |
| 34.8 (13.1–56.5)                      |
| 0.88                                   |
| 14.4 (9.1–19.7)                       |
| 0.81                                   |
| Normal (N=30)                          |
| 35.9 (1.7–70.1)                       |
| 9.6 (0.0–39.7)                        |
| 0.39                                   |
| Serum β2-MG                            |
| Elevated (N=7)                         |
| 26.1 (1.5–50.7)                       |
| 0.21                                   |
| 7.8 (4.4–11.2)                        |
| 0.01                                   |
| Normal (N=51)                          |
| Overall response                       |
| SD or PD or NE (N=16)                  |
| 2.7 (1.1–4.3)                         |
| 0.01                                   |
| 1.9 (1.5–3.3)                         |
| 0.01                                   |
| CR or PR (N=57)                       |
| 48.1 (34.6–61.6)                      |
| 0.04                                   |
| 18.9 (0.0–41.8)                       |
| 0.02                                   |
| ASCT                                   |
| No (N=46)                              |
| 20.6 (3.4–37.8)                       |
| 0.04                                   |
| 8.6 (1.7–15.5)                        |
| 0.02                                   |
| Yes (N=27)                             |
| 49.6 (31.6–67.6)                      |
| 0.04                                   |
| 18.9 (0.0–45.2)                       |
| 0.02                                   |

Abbreviations: ASCT, autologous stem cell transplantation; β2-MG, β2-microglobulin; CR, complete response; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; N/A, not applicable; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

| Table 4. Multivariate analysis. |
|--------------------------------|
| Overall survival               |
| Event-free survival            |
| Hazard ratio                   |
| 95% CI                         |
| P                              |
| Hazard ratio                   |
| 95% CI                         |
| P                              |
| Age ≥65                       |
| 2.15                           |
| 1.01–4.61                      |
| 0.04                           |
| 1.26                           |
| 0.58–2.74                      |
| 0.56                           |
| Multifocal lesions             |
| 2.58                           |
| 1.13–5.87                      |
| 0.02                           |
| 2.37                           |
| 1.07–5.25                      |
| 0.03                           |
| High CSF protein concentration |
| 2.38                           |
| 1.19–4.75                      |
| 0.01                           |
| 1.69                           |
| 0.82–3.48                      |
| 0.16                           |
| ECOG PS ≥2                     |
| 0.03                           |
| 0.53–2.23                      |
| 0.83                           |
| 0.96                           |
| 0.46–2.01                      |
| 0.91                           |
| Deep region involvement        |
| 0.76                           |
| 0.38–1.60                      |
| 0.50                           |
| 1.02                           |
| 0.50–2.08                      |
| 0.95                           |
| Elevated serum LDH             |
| 0.84                           |
| 0.46–1.87                      |
| 0.84                           |
| 1.20                           |
| 0.61–2.36                      |
| 0.61                           |

Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase.
at 2 and 5 years were 41% (95% CI, 35%–47%) and 24% (95% CI, 17%–31%), respectively. In univariate analysis, multifocal lesions and failure to achieve CR or PR after first chemotherapy were related with worse EFS, while multifocal lesions were the only factor associated with worse EFS in multivariate analysis (Tables 3 and 4).

In the subgroup analysis of patients aged younger than 65 years who received first-line chemotherapy, the median OS of those who received chemotherapy without ASCT (chemotherapy alone or chemotherapy followed by WBRT) was 34.8 months (N=24; 95% CI, 0.0–71.4 mo). By contrast, the median OS of those who received chemotherapy followed by ASCT was 48.1 months (N=25; 95% CI, 30.8–65.4 mo). They did not show any statistical differences in OS (P=0.62).
Table 5. Comparison of prognostic models.

| Variables                      | Previous models        | New model       |
|-------------------------------|------------------------|-----------------|
|                               | IELSG                  | Nottingham/Barcelona | MSKCC   | AMC     |
| Old age                       | > 60                   | > 60            | ≥ 50    | ≥ 65    |
| Poor performance ECOG PS      | ≥ 2                    | ≥ 2             | KPS < 70| Yes     |
| Elevated serum LDH            | Yes                    | Yes             | Yes     | Yes     |
| High CSF protein              | Yes                    | Yes             | Yes     | Yes     |
| Deep lesions                  | Yes                    | Yes             | Yes     | Yes     |
| Multifocal lesions            |                        |                  |         |         |

Risk stratifications (Sum of adverse clinical variables)

| Risk level | Low risk | Moderate risk | High risk | Highest risk |
|------------|----------|---------------|-----------|--------------|
| Score      | 0–1      | 2–3           | 4–5       | 3           |
| Class      | 0 (class 1) | 1 (class 2) | 2 (class 3) | 3 (very high) |

Abbreviations: AMC, Asan Medical Center; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IELSG, International Extranodal Lymphoma Study Group; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center.

Validation of the Western prognostic models

We identified 61 patients who were eligible for the IELSG prognostic scoring model. They were stratified into 3 groups according to the scores of 0 to 1 (N=21, 34.4%), 2 to 3 (N=28, 45.9%), and 4 to 5 (N=12, 19.7%). The "4 to 5" score group showed the worst survival outcome. However, the ability to discriminate patients in the "2 to 3" score group (median OS, 48.1 mo; 95% CI, 17.5–78.2 mo) from the "0 to 1" group (median OS, 41.9 mo; 95% CI, 6.7–77.1 mo) was not statistically significant (P=0.58) (Fig. 1). The Nottingham/Barcelona model was applicable to all 77 patients. They were grouped into 0 (N=26, 33.8%), 1 (N=32, 41.6%), 2 (N=14, 18.2%), and 3 (N=5, 6.5%). The median OS was 58.2 months in the "0" group (95% CI, 39.1–77.3 mo), 43.4 months in the "1" group (95% CI, 19.5–67.3 mo), 10.9 months in the "2" group (95% CI, 8.3–14.5 mo), and 1.8 months in the "3" group (95% CI, 0.9–2.7 mo) with statistical significance (P<0.01) (Fig. 2). All our patients were also eligible for the MSKCC prognostic model, and the median OS was 68.1 months in class 1 (N=19; 95% CI, N/A), 34.8 months in class 2 (N=42; 95% CI, 14.1–55.5 mo), and 19.2 months in class 3 (N=16; 95% CI, 15.3–23.1 mo) with statistical significance (P=0.03) (Fig. 3).

Newly proposed Asan Medical Center (AMC) prognostic model

Based on our findings, we assigned 1 point to each of the 3 adverse variables (age 65 or older, multifocal lesions, and high CSF protein concentration). A total score of 0 was designated as low risk, 1 as moderate risk, 2 as high risk, and 3 as very high risk. A total of 61 patients were found to be evaluable for this model, and the median survival was 58.2 months in the low-risk group (N=17), 34.8 months in the moderate-risk group (N=26), 9.0 months in the high-risk group (N=14), and 1.8 months in the very high-risk group (N=4) with statistical significance (P<0.01) (Fig. 4).

The comparisons of the prognostic models are summarized in Table 5.

DISCUSSION

If untreated, PCNSL is rapidly fatal. WBRT had been widely used as the first-line treatment for patients with PCNSL and has a median survival of approximately 1 year [16]. WBRT has been attempted to be combined with chemotherapy, but high rates of delayed neurotoxicities became problematic, particularly in vulnerable elderly patients. The introduction of high-dose MTX-based chemotherapeutic regimen in the 1990s improved the response rate and prolonged patient survival. Currently, the median survival of patients with PCNSL treated with MTX-based chemotherapy ranges from 14 months to 5 years [17]. High-dose chemotherapy followed by ASCT is now widely accepted as an alternative treatment modality in selected patients and can be used as first-line as well as salvage treatment. We recently reported good response rates, favorable tolerance profiles, and a 2-year survival rate of 88.9% from induction chemotherapy (5 cycles of high-dose MTX and 2 cycles of high-dose cytarabine) followed by conditioning with BUCYE (busulfan, cyclophosphamide, and etoposide) and then ASCT [18].

The most widely accepted prognostic markers for patients with PCNSL are age and performance status [1]. In our previous report, we found that age was the strongest prognostic factor for survival irrespective of treatment scheme. However, that study focused on relapse patterns of PCNSL, and the study population was heterogeneous in nature [10]. In the present study, we enrolled only patients who met the inclusion criteria (importantly, only those with diffuse large B-cell histology) to maximize homogeneity of a cohort. Moreover, age over 65 years, multifocal lesion, and high CSF protein concentrations were found to be independent
predictors for poor prognosis. Interestingly, chemotherapy followed by ASCT was associated with OS and EFS in univariate analysis but not in multivariate analysis. Thus, we performed a subgroup analysis of patients younger than 65 years old who received chemotherapy as first-line treatment to determine if chemotherapy followed by ASCT influences prognosis. However, no statistically meaningful survival differences were found between the 2 groups. This result might be due to the relatively small number of patients and different induction or conditioning regimens applied to the patients in the ASCT group.

Prognostic models that can help clinicians estimate patient prognosis, determine optimal treatment modalities, and facilitate clinical trials have been proposed by many researchers. However, the application of these models is limited by their complexity to use, weak cross-validity, and inherent heterogeneity among study populations. We found that the Nottingham/Barcelona and MSKCC models predicted our patients’ survival, but the IELSG model did not. In particular, the MSKCC model, which used recursive partitioning analysis technique to secure homogeneity, worked adequately to stratify the risk groups. However, we have to keep in mind that the Nottingham/Barcelona model was based on old-fashioned chemotherapy regimens, and the MSKCC model has an issue of selection bias.

Our newly designed model is based on 3 identified variables, namely, age, numbers of tumor, and CSF protein level. Unlike other models, the performance status was not a predictive factor for survival in our study. In our cohort, the proportion of patients with good performance status (ECOG PS < 2 or KPS ≥ 70) was relatively higher (74.0%) than that of the Western studies (IELSG, 31%; Nottingham/Barcelona, 36%; and MSKCC, 55%). This discrepancy may be attributed to the overestimation of clinician-reported performance status while collecting retrospective data and the sociocultural tendency to hide the severity of cancer-related symptoms. We found that the cut-off value of age was 65 years, which is an also important factor when deciding on stem cell transplantation for patients with lymphoma. Measuring the CSF protein level is sometimes contraindicated in patients suspected with increased intracranial pressure; however, most patients (61/77, 79.2%) underwent spinal tapping without compromising our scoring system. Involvement of the deep regions of the brain was considered important in the IELSG model, but subsequent studies, including our study, found no correlation between deep structural involvement and prognosis. In view of risk group stratifications, the Nottingham/Barcelona model and our model subdivide high-risk groups into “higher-” and “highest-” risk groups. In terms of homogeneity and treatment regimens, our model appears to be a better tool for predicting prognosis between the groups. As such, the AMC model can be an alternative tool for predicting prognosis in patients with primary CNS diffuse large B-cell lymphoma.

To identify other readily available predictors, we added serum β2-microglobulin and variables such as absolute lymphocyte count [19], neutrophil-to-lymphocyte ratio [20], and platelet-to-lymphocyte ratio [21] into our analyses. Contrary to our expectations, no factors were identified to be significantly associated with prognosis (data not shown). Further investigations on these variables are needed to confirm their usefulness.

The major limitations of our study are the possibility of selection bias due to the single-center, retrospective study design and lack of external validation. Our findings necessitate further validations by larger cohort, multicenter prospective clinical trials.

In our study, advanced age, multifocal lesions, and high CSF protein concentration were identified as adverse prognostic variables. In PCNSL, patients with pure diffuse large B-cell histology, new model can be useful in estimating patient prognosis.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Abrey LE. Primary central nervous system lymphoma. Curr Opin Neurol 2009;22:675-80.
2. Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20.
3. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8.
4. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-97.
5. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998;41:615-20.
6. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5.
7. Huang-Xuan K, Taillandier L, Chivot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003;21:2726-31.
8. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.
9. Bessell EM, Graus F, Lopez-Guillermo A, et al. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term
survival and prognostic factors. Int J Radiat Oncol Biol Phys 2004;59:501-8.
10. Kim JE, Yoon DH, Kim S, et al. Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma. Korean J Hematol 2012;47:60-6.
11. Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012;103:245-51.
12. Yamanaka R, Morii K, Shinbo Y, et al. Results of treatment of 112 cases of primary CNS lymphoma. Jpn J Clin Oncol 2008;38:373-80.
13. Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan—a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994;19:197-215.
14. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008.
15. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
16. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
17. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-92.
18. Yoon DH, Lee DH, Choi DR, et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant 2011;46:105-9.
19. Aoki K, Tabata S, Yonetani N, Matsushita A, Ishikawa T. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Acta Haematol 2013;130:242-6.
20. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010;85:896-9.
21. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-72.